A Clinical Investigation to Evaluate The Orkla Corn Plaster
Launched by ORKLA CARE AB · Oct 19, 2020
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Signed Informed Consent Form
- • 2. \>18 years of age
- • 3. Presence of corn(s) confirmed by Investigator
- • 4. Corn included into investigation shall not have been subject to any other treatment 1 month prior to study enrolment.
- Exclusion Criteria:
- • 1. Pregnant or lactating women at time of enrolment
- • 2. Subjects with hypersensitivity to salicylic acid/salicylates, polyethylene foil, acrylic adhesive, viscose/polyethylene fibers and azorubine
- • 3. Subjects diagnosed with diabetes
- • 4. Subjects with poor peripheral blood circulation
- • 5. Subjects with renal dysfunction (eGFR \<60 mL/min/1.73 m2)
- • 6. Subjects with ongoing skin disease in the area where the index corn is located.
- • 7. Subjects with any other condition that as judged by the investigator may make follow-up or investigations procedures inappropriate
- • 8. Any subject that according to the Declaration of Helsinki is unsuitable for enrollment
About Orkla Care Ab
Orkla Care AB is a leading company in the health and wellness sector, dedicated to developing innovative consumer products that enhance everyday living. As a sponsor of clinical trials, Orkla Care AB is committed to advancing scientific research and ensuring the safety and efficacy of its offerings. With a robust portfolio that includes dietary supplements, personal care products, and functional foods, the company emphasizes quality and sustainability in its operations. Leveraging cutting-edge research and collaboration with healthcare professionals, Orkla Care AB aims to contribute to improving public health outcomes and promoting a healthier lifestyle for consumers worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gothenburg, , Sweden
Patients applied
Trial Officials
Felix Lundin
Principal Investigator
Carlanderska Hospital, Carlandersparken 1, 405 45 Göteborg, Sweden.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials